Published in J Natl Cancer Inst Monogr on January 01, 1992
Prognostic and Predictive Factors for Breast Cancer. Breast Cancer (1995) 0.94
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ (1994) 23.80
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 9.10
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ (1994) 6.74
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Mortality in relation to smoking: 22 years' observations on female British doctors. Br Med J (1980) 5.21
Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 4.92
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet (2000) 4.39
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 4.26
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum (1990) 3.97
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med (1992) 3.55
Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol (1995) 3.51
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG (2007) 3.31
HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS (2001) 3.30
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med (1989) 3.21
Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol (2000) 3.10
Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem (1978) 3.05
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. Ann Intern Med (1990) 2.75
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand (2009) 2.68
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Consensus criteria for the classification of carpal tunnel syndrome in epidemiologic studies. Am J Public Health (1998) 2.53
The St. Jude valve. Thrombolysis as the first line of therapy for cardiac valve thrombosis. Circulation (1993) 2.51
Speech perception as a function of electrical stimulation rate: using the Nucleus 24 cochlear implant system. Ear Hear (2000) 2.51
Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology (1978) 2.42
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
The optimal timing of mastectomy: low tide or high tide? Ann Intern Med (1991) 2.40
Evaluation of a new spectral peak coding strategy for the Nucleus 22 Channel Cochlear Implant System. Am J Otol (1994) 2.37
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Horm Res (1969) 2.31
Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (1975) 2.29
Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst (1991) 2.29
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst (1996) 2.25
Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology (1978) 2.25
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol (2001) 2.20
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Current status of estrogen and progesterone receptors in breast cancer. Cancer (1977) 2.10
Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci (1993) 2.08
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst (1992) 2.05
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer (1990) 2.00
Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst (1993) 1.99
Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol (1978) 1.99